Ollin Biosciences is hiring for a role in the CMC engine behind next-generation ophthalmology therapeutics, including process development, validation, tech transfer, and BLA submission for Phase 3 assets in nAMD and DME, plus an earlier-stage thyroid eye disease program.

Public source

Publisher name

Public post

We're hiring! Join us as we build the CMC engine behind next-generation ophthalmology therapeutics. From process development to validation, tech transfer, and BLA submis…

Log in to read the full post

Company

Ollin Biosciences

Accelerating Next Generation Therapies for Ophthalmology

Industry
Biotechnology Research
Location
Austin, US
Company size
11–50 employees

About Ollin Biosciences

Ollin Biosciences is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology.

See more

Discover more

Similar public activity from other companies.

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.